ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares ManagementGlobeNewsWire • 12/18/23
ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and OlderGlobeNewsWire • 12/12/23
ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MDGlobeNewsWire • 11/16/23
ADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/08/23
ADMA Biologics to Report Third Quarter 2023 Financial Results on November 8, 2023GlobeNewsWire • 11/01/23
ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/09/23
ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023GlobeNewsWire • 08/02/23
ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GAGlobeNewsWire • 07/19/23
ADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/10/23
ADMA Biologics to Report First Quarter 2023 Financial Results on May 10, 2023GlobeNewsWire • 05/03/23
ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 03/23/23